144 related articles for article (PubMed ID: 3756067)
1. Sparteine oxidation is practically abolished in quinidine-treated patients.
Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
[TBL] [Abstract][Full Text] [Related]
2. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Nielsen MD; Brøsen K; Gram LF
Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
[TBL] [Abstract][Full Text] [Related]
4. Substantial rise in sparteine metabolic ratio during haloperidol treatment.
Gram LF; Debruyne D; Caillard V; Boulenger JP; Lacotte J; Moulin M; Zarifian E
Br J Clin Pharmacol; 1989 Feb; 27(2):272-5. PubMed ID: 2713222
[TBL] [Abstract][Full Text] [Related]
5. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
6. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Nielsen F; Rosholm JU; Brøsen K
Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
[TBL] [Abstract][Full Text] [Related]
8. Sparteine oxidation polymorphism in Denmark.
Brøsen K; Otton SV; Gram LF
Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
[TBL] [Abstract][Full Text] [Related]
9. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
[TBL] [Abstract][Full Text] [Related]
10. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
Brøsen K
Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
[TBL] [Abstract][Full Text] [Related]
11. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
Inaba T; Tyndale RE; Mahon WA
Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
[No Abstract] [Full Text] [Related]
12. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
14. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
[TBL] [Abstract][Full Text] [Related]
15. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
Kaneko K; Atsumi T; Miyataka T
Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
[TBL] [Abstract][Full Text] [Related]
16. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
17. A simple borohydride/GC method for measuring sparteine metabolites in man.
Inaba T; Vinks A; Otton SV
Br J Clin Pharmacol; 1986 May; 21(5):473-80. PubMed ID: 3718806
[TBL] [Abstract][Full Text] [Related]
18. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
19. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
20. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]